Following EC’s approval, the company is now set to launch the spray in September 2011.
Developed by Nycomed, Instanyl fentanyl nasal spray will be launched in 50µg, 100µg, and 200µg strengths.
Norwegian University of Science and Technology professor Stein Kaasa said the launch of the single-dose nasal spray will ease the management of dose titration and modification, which together with the nasal spray’s safety and convenience should contribute to further improving the management of breakthrough pain.